Cargando…
Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with documented progression on or within 6 months after...
Autores principales: | Lee, Keun-Wook, Kim, Jee Hyun, Yun, Tak, Song, Eun Kee, Na, Im il, Shin, Hyunchoon, Oh, So Yeon, Choi, In Sil, Oh, Do-Youn, Kim, Dong-Wan, Im, Seock-Ah, Kim, Tae-You, Lee, Jong Seok, Heo, Dae Seog, Bang, Yung-Jue, Kim, Noe Kyeong |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694374/ https://www.ncbi.nlm.nih.gov/pubmed/17923737 http://dx.doi.org/10.3346/jkms.2007.22.S.S115 |
Ejemplares similares
-
Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2010) -
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008) -
Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005) -
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
por: Lee, Dae-Won, et al.
Publicado: (2017) -
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
por: Lee, Kyung-Hun, et al.
Publicado: (2007)